Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -41.77% is 77% above its 5-year average of -184.78%, around the middle of its 5-year range (-921.82%–379.58%).
85.95% above its 12-month average of -297.31%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 66.00%.
EBITDA MARGIN
-41.77%
EBITDA MARGIN AVG TTM
-297.31%
EBITDA MARGIN AVG 3Y
-144.15%
EBITDA MARGIN AVG 5Y
-184.78%
EBITDA MARGIN AVG 10Y
-282.15%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+85.95%
CURRENT VS 3Y AVG
+71.02%
CURRENT VS 5Y AVG
+77.39%
CURRENT VS 10Y AVG
+85.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Arvinas, Inc.
Market Cap
$476.17M
EBITDA Margin
-41.77%
TTM Avg
-297.31%
3Y Avg
-144.15%
5Y Avg
-184.78%
Market Cap
$478.28M
EBITDA Margin
-9.71%
TTM Avg
-10.19%
3Y Avg
-20.82%
5Y Avg
-63.11%
Market Cap
$474.97M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$472.58M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
Market Cap
$462.71M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$460.20M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$457.20M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $476.17M | -41.77% | -297.31% | -144.15% | -184.78% |
| Evolus, Inc. (EOLS)vs › | $478.28M | -9.71% | -10.19% | -20.82% | -63.11% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.97M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $472.58M | -3.52% | -5.19% | -11.78% | -23.46% |
| NRC Health (NRC)vs › | $463.35M | 21.99% | 25.40% | 28.98% | 31.97% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $462.71M | -31.76% | -31.76% | -31.76% | -31.76% |
| Kamada Ltd. (KMDA)vs › | $460.98M | 22.80% | 21.92% | 17.96% | 15.83% |
| NeoGenomics, Inc. (NEO)vs › | $460.20M | 0.24% | -1.36% | -6.49% | -5.53% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $457.20M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $507.38M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
Gross Margin
96.4%
EBITDA Margin
-41.8%
Operating Margin
-43.8%
Net Margin
2.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 66.00% |
| 2026-03-31 | -394.87% |
| 2025-12-31 | -742.11% |
| 2025-09-30 | -102.63% |
| 2025-06-30 | -312.95% |
| 2025-03-31 | 38.51% |
| 2024-12-31 | -95.61% |
| 2024-09-30 | -57.81% |
| 2024-06-30 | -61.18% |
| 2024-03-31 | -322.53% |
| 2023-12-31 | 379.58% |
| 2023-09-30 | -208.67% |
| 2023-06-30 | -133.94% |
| 2023-03-31 | -264.62% |
| 2022-12-31 | -192.89% |
| 2022-09-30 | -187.35% |
| 2022-06-30 | -189.05% |
| 2022-03-31 | -209.81% |
| 2021-12-31 | -200.92% |
| 2021-09-30 | -495.70% |
| 2021-06-30 | -921.82% |
| 2021-03-31 | -738.18% |
| 2020-12-31 | -1890.59% |
| 2020-09-30 | -403.56% |
| 2020-06-30 | -445.80% |
| 2020-03-31 | -362.60% |
| 2019-12-31 | -451.00% |
| 2019-09-30 | 20.34% |
| 2019-06-30 | -446.37% |
| 2019-03-31 | -383.12% |
| 2018-12-31 | -486.04% |
| 2018-09-30 | -410.85% |
| 2018-06-30 | -245.57% |
| 2018-03-31 | -101.23% |
| 2017-12-31 | -202.39% |
| 2017-09-30 | -379.15% |
| 2017-06-30 | -397.56% |
| 2017-03-31 | -374.18% |
